NGS in AML Relapse

Acute Myeloid Leukemia Clinical Trial

— NGSAML  

Official title:

Retrospective Study of AML Relapses Using Targeted NGS Analysis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03582241
• Other study ID #: 7106
• Status: Recruiting
• Start date: June 27, 2018
• Est. completion date: June 2019

Study information

• Verified date: June 2018
• Source: University Hospital, Strasbourg, France
• Contact: Laurent MAUVIEUX, MD, PhD
• Phone: 33 3 88 12 75 27
• Email: laurent.mauvieux[@]chru-strasbourg.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Acute myeloid leukemia (AML) relapse is often associated with a clonal evolution at the cytogenetic and molecular level and therefore represents a challenge in the treatment of AML. Targeted sequencing is now usually done at diagnosis in AML, as only a small core group of genes is frequently mutated in AML and myelodysplastic syndromes. This approach, contrary to WGS is cheaper, together with a rapid turnaround and high sequencing coverage depths allowing the detection of variant allele fractions as low as 2%.

In the investigator's center, targeted analysis of AML patients is routinely realized at diagnosis and at relapse. In thses patients, five different clonal evolution patterns including cytogenetic and molecular analysis at relapse will be evaluated: (1) Stability, defined by no clonal change, (2) Gain, strictly defined by acquisition of additional variations (mutations or cytogenetic alterations), (3) Loss, strictly defined by loss of variants or regression, (4) Gain and Loss, indicating the combination of both Gain and Loss patterns, (5) Emergence, defined by the emergence of alterations that were unrelated to those found at diagnosis.

Karyotype and the mutations of up to 40 AML patients benefited from targeted NGS in the clinical hematology laboratory of the Hopitaux Universitaires de Strasbourg both at the time of the diagnosis of and the relapse will be studied, together with clinical and other biological characteristics.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: June 2019
• Est. primary completion date: June 2019
• Gender: All
• Age group: 18 Years and older

Eligibility

• Inclusion criteria:

• patients with AML that relapsed studied in the clinical laboratory of hematology of the Hopitaux Universitaires de Strasbourg, France

• given consentment or non-opposition for retrospective anonymous analysis of clinical and data

• Exclusion criteria:

• person under tutorship-

• persons who asked to withdraw from the study

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Recurrence

Locations

Country	Name	City	State
France	Laboratoire d'Hématologie	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall survival of the different clonal evolution patterns		6 months